RecruitingPhase 1NCT07361354
A Phase 1 Ethnobridging TriaL of AGA2118 in Healthy Japanese, Chinese, and Caucasian ParticipantS (ATLAS)
A Phase 1, Randomized, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of AGA2118 in Healthy Japanese, Chinese, and Caucasian Participants
Sponsor
Angitia Incorporated Limited
Enrollment
30 participants
Start Date
Jan 5, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
This study will evaluate the effects of a single dose of AGA2118 in Japanese, Chinese, and Caucasian participants
Eligibility
Min Age: 18 YearsMax Age: 65 Years
Inclusion Criteria3
- Healthy males or females, aged 18 to 65 years
- hydroxyvitamin D ≥30 ng/mL and agree to taking calcium and vitamin D supplements during the study
- Meet the criteria for Japanese, Chinese, or Caucasian ethnicity
Exclusion Criteria6
- Participating or have participated in another clinical trial within the past 6 months
- Any bone fracture within the past 6 months
- History of myocardial infarction or stroke within the past 12 months
- Malignancy within the past 5 years
- Current hyper- or hypocalcemia
- Pregnant or breastfeeding women, or women planning to become pregnant during the study
Interventions
DRUGAGA2118
Participants will receive AGA2118 administered by subcutaneous injection
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07361354
Related Trials
A Study to Investigate the Pharmacokinetics of Different Formulations and Safety of AZD5004 in Healthy Participants Aged 18 to 55 Years
NCT074558252 locations
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
NCT074041371 location
Cognitive Strategies in Early Psychosis 1
NCT072314971 location
Evaluation of See.d as an Automated Blood Sample Preparator for Multiple Liquid Biopsy Applications
NCT060971561 location
OCTA in Cardiovascular Disease and Healthy Controls
NCT073596641 location